• About Fuad El-Hibri
• Log in

• Abdul Aziz Said
• American Society of Hematology
• American University
• Arab
• BioDefense
• biotechnology
• Biotechnology and Pharmaceuticals
• BioThrax
• Board of Trustees
• Business
• CEO
• Chief executive officer
• Chief financial officer
• Chief Medical Officer
• Chief operating officer
• Clinical trial
• colleagues
• Crisis
• disease
• Dr. Mary Elizabeth King
• El-Hibri
• El-Hibri Fuad
• El-Hibri Peace Education Prize
• Emergent
• Emergent BioSolutions
• Emergent BioSystems
• Entrepreneur
• Ernst & Young
• Ernst & Young Entrepreneur of the Year
• Federal government of the United States
• Financial Performance
• Financial Results
• Food and Drug Administration
• Food and Drug Administration
• Foundation
• Fuad El-Hibri
• Fuad Elhibri
• Healthcare
• Healthcare Conference
• Hematology
• Hudson Institute
• Ibrahim El-Hibri
• Ibrahim Y. El-Hibri
• Investors
• Lebanese
• Lymphocyte
• Lymphoma
• Maryland
• Medical
• Music
• National Health Museum
• North Atlantic Treaty Organization
• NuThrax
• NYSE
• Peace Education
• Resource Center
• Revenue
• Sage Hall
• Scholars Program
• Securities and Exchange Commission
• Shareholders
• South Africa
• Tech Council of Maryland
• technology
• Trubion Pharmaceuticals
• Tuberculosis Vaccine
• U.S. Food and Drug Administration
• Uncategorized
• United States
• United States Department of Defense
• United States Department of Health and Human Services
• Vaccine
• Washington
• World Health Organization
• World TB
• Yale University

Category Archives: Vaccine

1. CEO took roundabout path to Emergent January 7, 2011

   Posted in Business, Chief executive officer, El-Hibri, Emergent BioSolutions, Entrepreneur, Food and Drug Administration, Fuad El-Hibri, Trubion Pharmaceuticals, United States, United States Department of Health and Human Services, Vaccine, Yale University, biotechnology.

   No comments
2. Emergent BioSolutions to Release Third Quarter 2010 Financial Results and Conduct a Conference Call on November 4, 2010 October 23, 2010

   Posted in BioThrax, Chief executive officer, Emergent BioSolutions, Fuad El-Hibri, NYSE, Vaccine.

   No comments
3. Emergent BioSolutions Awarded HHS Contract Valued at up to $186.6 Million to Develop rPA Anthrax Vaccine September 20, 2010

   Posted in BioThrax, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri, United States, United States Department of Health and Human Services, Vaccine.

   No comments
4. Emergent BioSolutions Awarded NIAID Contract That Increases Potential Funding to Over $58 Million for Advanced Development of Third Generation Anthrax Vaccine September 10, 2010

   Posted in BioThrax, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri, Vaccine.

   No comments
5. Emergent Revises Upward 2010 Financial Forecast August 3, 2010

   Posted in BioThrax, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri, Maryland, United States, Vaccine.

   No comments
6. Maryland Governor Martin O’Malley Leads Ribbon Cutting Ceremony at Emergent’s Baltimore Manufacturing Facility July 27, 2010

   Posted in BioThrax, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri, United States, Vaccine.

   No comments
7. Emergent BioSolutions Awarded HHS Contract Valued at Up to $107 Million to Develop Large-Scale Manufacturing for BioThrax July 15, 2010

   Posted in BioThrax, Chief executive officer, Emergent BioSolutions, Food and Drug Administration, Fuad El-Hibri, United States, United States Department of Health and Human Services, Vaccine.

   No comments
8. Washington Launched Me, But I am Proud to be a Lebanese Dreaming of New Technology - Al Anwar October 14, 2009

   Posted in Lebanese, Medical, Vaccine, Washington, disease, technology.

   No comments